Coherus BioSciences, Inc.

CHRS

US19249H1032

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
1.91 ^USD	-4.98%		-11.98%	-42.64%

05-23	Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 Antibody, CHS-114, at the 2024 American Society of Clinical Oncology Annual Meeting	CI
05-13	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating	MT

Coherus BioSciences, Inc. announced that it has received $38.7 million in funding

May 08, 2024

Coherus BioSciences, Inc. announced that it has received $38.7 million in a round of funding on May 9, 2024. The company has issued term loan in the transaction. The loan will mature in May 2029.

Latest news about Coherus BioSciences, Inc.

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 Antibody, CHS-114, at the 2024 American Society of Clinical Oncology Annual Meeting	05-23	CI
Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating	05-13	MT
Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M	05-09	MT
Coherus BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Coherus Biosciences, Inc. Enters into a Senior Secured Term Loan Facility	05-09	CI
Coherus BioSciences, Inc. Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan	05-09	CI
Coherus BioSciences, Inc. announced that it has received $38.7 million in funding	05-08	CI
Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer	05-08	CI
Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting	04-24	CI
HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	03-20	MT
Coherus BioSciences Shares Fall After Workforce Reduction Plan; Q4 Loss	03-14	MT
Transcript : Coherus BioSciences, Inc., Q4 2023 Earnings Call, Mar 13, 2024	03-13
Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q4 Revenue $91.5M, vs. Street Est of $90.4M	03-13	MT
Coherus BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-13	CI
North American Morning Briefing : Stock Futures -2-	03-04	DJ
North American Morning Briefing : Stock Futures Hover At Start of Busy Week	03-04	DJ
Coherus BioSciences Completes $170 Million Sale of Ophthalmology Franchise to Sandoz	03-04	MT
Sandoz: acquisition of Cimerli finalized	03-04	CF
Sandoz Completes Purchase of Retinal Disease Medication Cimerli from Coherus BioSciences	03-04	MT
Sandoz Inc. completed the acquisition of CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc..	02-29	CI
Coherus Biosciences, Inc. Appoints Georgia Erbez to Board of Directors	02-22	CI
Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv	02-21	CI
KKR to acquire a stake in health tech firm Cotiviti	02-14	RE
BioPharma Credit to receive partial prepayment of loan	02-06	AN

Chart Coherus BioSciences, Inc.

Duration

Period

More charts

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Coherus BioSciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.01 USD

Average target price

8.333 USD

Spread / Average Target

+314.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COHERUS BIOSCIENCES, INC.	-42.64%	231M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	116B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-15.33%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.14B
SAREPTA THERAPEUTICS, INC.	+28.03%	12.02B

Bio Therapeutic Drugs